Biosidus Scales Up Biologics Output to Meet Global Rare Disease Demand

The facility upgrade arrives as healthcare systems globally prioritize the continuity of care for patients with chronic conditions. For Biosidus, this industrial expansion serves as a cornerstone for its broader strategy to increase access to complex biologic medicines beyond its domestic market. The company, which launched its agalsidase beta biosimilar in Argentina last year, is positioning itself as a reliable partner for health authorities seeking to diversify their sources of critical treatments.

Mario Koch, Director of Rare Diseases at Biosidus, emphasized that the investment is driven by the necessity of stable treatment for rare disease patients. With the new bioreactor capacity now operational, the firm is prepared to initiate discussions with international partners to address specific supply requirements where regulatory frameworks permit. This development marks a significant step in the company’s evolution, moving from a regional manufacturer to a contender in the global supply of specialized biologics.